Lung cancer is the leading cause of cancer death globally. Each year, 1.59 million people die as a result of the disease, which means more than 4,350 deaths worldwide every day. Lung cancer can be broadly divided into two major types, NSCLC and small cell lung cancer. NSCLC is the most prevalent type, accounting for around 85% of all cases.
New Drug developments
Novartis announced on May 8, 2015 that its lung cancer drug Zykadia (certinib) was approved for use within the European Union. Zykadia is used to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). The patients should be previously treated with crizotinib. The EU joins a list of 10 countries, […]
Brigatinib is an investigational oral inhibitor of anaplastic lymphoma kinase (ALK). Brigatinib was internally discovered by ARIAD scientists, and targets unique genetic features of cancer cells. ALK was first identified as a chromosomal rearrangement in anaplastic large-cell lymphoma (ALCL). Genetic studies indicate that abnormal expression of ALK is a key driver of certain types of […]
Japan becomes first country to approve Roche’s alectinib for people with a specific form of advanced lung cancer Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved […]
AZD9291 is a potent, selective, irreversible inhibitor of both EGFR sensitising and T790M resistance mutations with less activity towards wild-type EGFR. It inhibits phosphorylation of mutant-EGFR and wild–type EGFR in cells in vitro with IC50 potencies < 100nM and 0.5 – 2 µM, respectively. AZD9291 exhibits moderate potency against erbB2: it remains to be determined whether sufficient […]
Dabrafenib targets BRAF, a key component of the MAPK (mitogen-activated protein kinase) pathway. In many types of melanoma, a mutated BRAF protein on the MAPK pathway disrupts normal cellular regulation and promotes increased cell production. Dabrafenib binds to the mutated BRAF protein, which may lead to an inhibition of oncogenic signalling, thus inhibiting the proliferation […]
Alectinib (RG7853/AF-802/RO5424802/CH5424802) is an investigational oral medicine created at Chugai Kamakura Research Laboratories and is being developed for people with NSCLC whose tumours are identified as ALK+. ALK+ NSCLC is often found in younger people, women and those who have a light or non-smoking history. It is almost always found in people with a specific […]